glioblastoma
Oncology · 2019–2019
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| bevacizumab Treatment of relapsed or refractory glioblastoma in patients who have progressed on or are intolerant to temozolomide. | Mar 2019 | Deferred | 783 individuals Cure Brain Cancer Foundation · Brain Cancer Group · Brain Tumour Alliance Australia · Co-operative Trials Group · Clinical Oncology Society of Australia Neuro-oncology · Medical Oncology Group |
Who spoke
Cure Brain Cancer Foundation · Brain Cancer Group · Brain Tumour Alliance Australia · Co-operative Trials Group · Clinical Oncology Society of Australia Neuro-oncology · Medical Oncology Group
What the PBS pays
$49M in government benefit over 2024–25, across 78,306 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| bevacizumab | $49.4M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.